by Mehek Punatar, Healthcare Analyst

Through Manhattan Research's new Digital Competitive Landscape offering, we analyzed five HCP product websites across the oncology space to create a digital competitive audit scorecard. Among the products tracked were: Avastin, Neulasta, Xtandi, Erbitux and Alimta. HCP product websites were scored on the basis of four major criteria: discoverability, usability, media & content, and service & communication. Each criterion had numerous sub-metrics.

HCP product websites were scored on four major criteria:

  • Discoverability assessed a website's search engine performance and traffic share;
  • Usability analyzed the desktop and mobile performance of a website;
  • Media and content assessed the presence of video, interactive tools, apps and social media;
  • Service and communication examined value-added support features such as sample ordering, rep access and more.

The Slideshare below shows the scorecard for the five websites we looked at:

Here's a quick summary of how they stacked up:

  • All five websites analyzed ranked very poorly for media and content, with none having any interactive tools, links to HCP apps or links to HCP social media.
  • The websites ranked about average on discoverability and usability, with all websites ranking low on domain authority (a prediction of how well a website performs in search engine rankings) and mobile speed.
  • The one criterion on which these sites showed some promise was service and communication, since most HCP product websites provide some form of value-added support for HCPs and branded support programs for patients.

Takeaway: The scorecard reveals gaps in pharma industry website strategy that might render the experience below average for the user, and so require urgent attention from pharma marketers.

DRG becomes Clarivate

View Now